


**Product Name: Recombinant Human IL-17A**  
**Catalog #: PEH0876**



## Summary

<b>Name</b>	IL-17A/Interleukin-17A
<b>Purity</b>	Greater than 95% as determined by reducing SDS-PAGE
<b>Endotoxin level</b>	<1 EU/μg as determined by LAL test.
<b>Construction</b>	Recombinant Human Interleukin-17A is produced by our E.coli expression system and the target gene encoding Gly24-Ala155 is expressed.
<b>Accession #</b>	Q16552
<b>Host</b>	E.coli
<b>Species</b>	Human
<b>Predicted Molecular Mass</b>	15.26 KDa
<b>Formulation</b>	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
<b>Stability&amp;Storage</b>	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
<b>Reconstitution</b>	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

## SDS-PAGE image



## Background

**Product Name: Recombinant Human IL-17A**  
**Catalog #: PEH0876**

---

**Alternative Names**

Interleukin-17A; IL-17; IL-17A; Cytotoxic T-Lymphocyte-Associated Antigen 8; CTLA-8; IL17A; CTLA8; IL17

**Background**

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

**Note**

For Research Use Only , Not for Diagnostic Use.